Multicenter retrospective study of capmatinib for non-small cell lung cancer with MET exon 14 skipping mutation

MET exon 14 skipping mutations (METex14) are found in 3% of non-small cell lung cancer (NSCLC) patients. These patients derive only modest benefit from standard NSCLC treatments. Capmatinib is a selective MET inhibitor. The IFCT-2104 CAPMATU study evaluated capmatinib among patients with METex14 NSCLC in a French early access program. The median age was 74.9 years. 56.6% were never-smokers, and 32.4% had brain metastases. From capmatinib initiation, the median time ot treatment failure was 5.1 months (95% CI 4.2-6.0) whereas the median progression-free survival was 4.8 months (4.0-6.0) and the median overall survival was 10.4 months (8.3-3.2). The median PFS was 7.7 months for treatment-naïve patients and 6.0 and 4.1 months for patients who received one or 2+ prior lines of treatment, respectively. For patients with brain metastases, the median PFS was 3.0 months. Among response evaluable patients, the objective response rate was 55.3% (95% CI 46.8-63.6). Grade 3 or 4 adverse events were seen in 17.8% of patients. The authors conclude that capmatinib was active for METex14 NSCLC, even in patients with brain metastases and previously treated patients, with a manageable safety.